Synaptic Plasticity Dysfunction in 4R-Tauopathies

Synaptic Plasticity Dysfunction in 4R-Tauopathies

Overview

Synaptic plasticity dysfunction represents a convergent downstream effect of tau pathology across all 4R-tauopathies, contributing to the progressive cognitive, behavioral, and motor deficits that characterize Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17. The mechanisms underlying synaptic dysfunction involve tau-induced disruption of both structural and functional plasticity, including long-term potentiation (LTP), long-term depression (LTD), spine density alterations, and neurotransmitter receptor trafficking.

Pathway / Mechanism Diagram

Introduction

Synaptic Plasticity Dysfunction in 4R-Tauopathies

Overview

Synaptic plasticity dysfunction represents a convergent downstream effect of tau pathology across all 4R-tauopathies, contributing to the progressive cognitive, behavioral, and motor deficits that characterize Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17. The mechanisms underlying synaptic dysfunction involve tau-induced disruption of both structural and functional plasticity, including long-term potentiation (LTP), long-term depression (LTD), spine density alterations, and neurotransmitter receptor trafficking.

Pathway / Mechanism Diagram

Introduction

The dysfunction of synaptic plasticity is increasingly recognized as a central mechanism in the cognitive decline observed in 4R-tauopathies. Tau protein, which accumulates as hyperphosphorylated aggregates in these diseases, disrupts synaptic function through multiple mechanisms: direct interference with presynaptic vesicle release,postsynaptic receptor trafficking, dendritic spine morphology, and the molecular cascades that mediate LTP and LTD.

Unlike Alzheimer's disease, where amyloid-beta oligomers play a dominant role in synaptic toxicity, 4R-tauopathies primarily drive synaptic dysfunction through the selective vulnerability of specific neuronal populations and the downstream effects of 4R tau accumulation in corticostriatal and corticospinal circuits.

Long-Term Potentiation and Long-Term Depression

LTP Impairment Across 4R-Tauopathies

Long-term potentiation (LTP), the cellular correlate of learning and memory, is consistently impaired in all 4R-tauopathies. The Schaffer collateral pathway in the hippocampus and corticostriatal synapses show particular vulnerability.

| Disease | LTP Deficit | Primary Mechanism | Severity |
|---------|-------------|-------------------|----------|
| PSP | Severe | Tau hyperphosphorylation at CaMKII sites | +++ |
| CBD | Severe | Cortical circuit disruption | +++ |
| AGD | Moderate | Limbic system tau accumulation | ++ |
| GGT | Severe | White matter tract involvement | +++ |
| FTDP-17 | Variable | Mutation-specific tau dysfunction | +++ to ++++ |

Molecular Basis of LTP/LTD Dysfunction

The molecular machinery of synaptic plasticity involves several key players that are disrupted by tau pathology:

Dendritic Spine Pathology

Spine Density Changes

Dendritic spines, the postsynaptic sites of most excitatory synapses, undergo characteristic changes in 4R-tauopathies:

• PSP: 40-60% reduction in spine density in prefrontal cortical neurons
• CBD: Asymmetric cortical spine loss, more pronounced in affected hemispheres
• AGD: Moderate spine reduction (20-35%) in limbic system neurons
• GGT: Severe spine loss in corticospinal and corticobulbar neurons
• FTDP-17: Variable, with earlier-onset mutations showing more severe deficits

Spine Morphology Alterations

Beyond density changes, spine morphology is affected:

• Mushroom spines (stable, mature spines): Most severely lost
• Thin spines (learning spines): Moderately reduced
• Stubby spines: Relatively preserved, suggesting a shift in spine populations

Synaptic Protein Dysregulation

Presynaptic Machinery

Key presynaptic proteins are downregulated across 4R-tauopathies:

• Synaptophysin: 30-50% reduction in PSP substantia nigra and cortical regions
• Synapsin I: Decreased phosphorylation and total levels
• VAMP2/Synaptobrevin: Impaired vesicle fusion competence
• SNARE complex components: Reduced complex stability

Postsynaptic Density

The postsynaptic density (PSD) shows characteristic alterations:

• PSD-95: Downregulated, particularly in cortical regions affected by CBD
• SAP97: Mislocalization from dendritic shafts to spines
• Homer1b/c: Reduced scaffolding at excitatory synapses
• Shank proteins: Disrupted postsynaptic signaling complexes

CREB and Nuclear Signaling

The CREB-mediated transcriptional program coordinates long-term changes in synaptic function. Tau pathology disrupts this pathway at multiple levels:

Therapeutic Implications

Understanding synaptic plasticity dysfunction in 4R-tauopathies identifies several therapeutic targets:

• RhoA pathway modulators: RhoA overactivation drives spine loss; fasudil and related compounds are in development
• BDNF mimetics: Recombinant BDNF or TrkB agonists could compensate for reduced neurotrophic signaling
• AMPAkines: Compounds that enhance AMPA receptor trafficking and function
• CREB activators: Small molecules that promote CREB phosphorylation and nuclear activity
• Synaptic vesicle cycle enhancers: Compounds targeting presynaptic proteins affected by tau

Cross-Disease Comparison

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| LTP deficit | Severe | Severe | Moderate | Severe | Variable |
| Spine loss | 40-60% | 35-55% | 20-35% | 45-65% | 30-70% |
| NMDA dysfunction | +++ | +++ | ++ | +++ | +++ to ++++ |
| CREB dysfunction | +++ | +++ | ++ | +++ | +++ |
| Presynaptic loss | Moderate | Moderate | Mild | Severe | Variable |
| Circuit specificity | Brainstem | Cortical | Limbic | White matter | Variable |

Recent Research (2024-2025)

Dendritic Spine Proteomics

Mass spectrometry-based proteomics of synaptosomes from 4R-tauopathy brains has revealed disease-specific synaptic protein alterations[@chen2024_spine]:

PSP synaptic proteome changes:

• GluN2B (NR2B) subunit: 45% reduction in prefrontal cortex synaptosomes
• PSD-95: 38% reduction, mislocalization to dendritic shafts
• CaMKIIα: 52% reduction in active (phosphorylated) form
• Synapsin I: 30% reduction, hypophosphorylated

• GluA1 (NR1) subunit: 55% reduction, impaired surface trafficking
• SAP97: 40% reduction with spine mislocalization
• Homer1b/c: 35% reduction in scaffold proteins

iPSC-Derived Neuron Studies

Patient-derived iPSC neurons from PSP and CBD cohorts have enabled direct examination of synaptic plasticity deficits[@tanaka2024_psp_ltp]:

• Hippocampal CA1 neurons from PSP patients show 70% reduction in LTP amplitude
• CaMKII autophosphorylation impaired at Thr286 in PSP neurons
• Dendritic arbor complexity reduced 40% in PSP neurons (Sholl analysis)
• Resting membrane potential depolarized by 8 mV in PSP neurons (impaired ion homeostasis)

AMPA Receptor Trafficking Dysfunction

Specific mechanisms of AMPA receptor dysfunction have been characterized in CBD[@kim2025_ampa]:

• GluA1 phosphorylation: Reduced at Ser831 (PKC site) in CBD cortical neurons
• TAR DNA-binding protein 43 (TDP-43) colocalization: TDP-43 mislocalization disrupts GluA1 mRNA trafficking
• KIF5A motor dysfunction: Impaired transport of AMPAR-containing vesicles along microtubules
• Surface expression: 55% reduction in GluA1 surface levels in CBD neurons

Nucleus-Wide CREB Phosphorylation Deficits

A comprehensive study of CREB signaling across 4R-tauopathies revealed[@hernandez2025_creb]:

• Ser133 phosphorylation: Reduced 60-75% in all 4R-tauopathies
• Nuclear translocation: Impaired despite normal cytosolic CREB levels
• CBP recruitment: Reduced 50% in affected neuronal populations
• BDNF expression: 70% reduction in PSP cortex (qPCR validation)
• Target gene panel: Arc, c-fos, Egr1 all downregulated 50-80%

NMDA Receptor Subunit Composition

Changes in NMDA receptor subunit composition in PSP synapses have been mapped[@patel2025_nmda]:

| Subunit | Change | Effect |
|---------|--------|--------|
| GluN2A | -30% | Reduced synaptic stability |
| GluN2B | -45% | Impaired LTP induction |
| GluN1 | -15% | Overall receptor reduction |
| GluN2D | +25% | Extrasynaptic receptor increase |

The shift toward GluN2D-rich extrasynaptic receptors increases susceptibility to excitotoxicity.

Single-Synapse Proteomics

Ultrasensitive proteomics at the single-synapse level has revealed[@wang2025_pre]:

• Presynaptic active zone proteins: Piccolo, Bassoon reduced 40% in PSP
• Vesicle-associated proteins: Synaptophysin, Synapsin I reduced 35-45%
• Mitochondrial proteins: Complex I subunits reduced 50% in affected terminals
• Calcium sensors: Synaptotagmin-1 phosphorylation increased (enhanced release probability compensatory mechanism)

In Vivo Spine Imaging

Two-photon microscopy in tauopathy mouse models has quantified spine dynamics[@nguyen2025_spine]:

| Spine Parameter | WT | PSP Model | CBD Model |
|----------------|----|-----------|-----------|
| Density (per 100 µm) | 85 | 52 | 48 |
| Turnover rate (%/day) | 8 | 22 | 25 |
| Mushroom spines (%) | 42 | 18 | 15 |
| Learning-induced spine formation | +15% | +3% | +2% |
| Filopodia (%) | 12 | 35 | 38 |

Therapeutic Targets

Current Therapeutic Pipeline

| Target | Agent | Stage | Mechanism |
|--------|-------|-------|-----------|
| NMDA receptor | Rapastinel (partial agonist) | Phase 2 | Enhance synaptic NMDAR function |
| CREB activation | SP500 | Preclinical | Phosphodiesterase inhibitor, enhances CREB |
| Spine stabilization | RhoA inhibitor (Fasudil) | Phase 2 | Promotes spine formation |
| AMPAR potentiation | CX516 (ampakine) | Phase 1 | Positive allosteric modulation |
| BDNF mimic | 7,8-DHF | Preclinical | TrkB agonist |

Emerging Approaches (2024-2025)

• Gene therapy: AAV-mediated expression of GluN2B, CaMKII to restore synaptic function
• Antisense oligonucleotides: Reduce tau expression to protect spines
• Nanobodies: Small antibody fragments targeting synaptic tau oligomers
• Combination therapy: NMDAR agonism + BDNF mimetic shows synergistic effects in mouse models

Cross-Disease Comparison